• Something wrong with this record ?

The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials

M. Snajdauf, K. Havlova, J. Vachtenheim, A. Ozaniak, R. Lischke, J. Bartunkova, D. Smrz, Z. Strizova

. 2021 ; 8 (-) : 628332. [pub] 20210310

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21018185

TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) and its death receptors TRAIL-R1 and TRAIL-R2 selectively trigger the apoptotic cell death in tumor cells. For that reason, TRAIL has been extensively studied as a target of cancer therapy. In spite of the promising preclinical observations, the TRAIL-based therapies in humans have certain limitations. The two main therapeutic approaches are based on either an administration of TRAIL-receptor (TRAIL-R) agonists or a recombinant TRAIL. These approaches, however, seem to elicit a limited therapeutic efficacy, and only a few drugs have entered the phase II clinical trials. To deliver TRAIL-based therapies with higher anti-tumor potential several novel TRAIL-derivates and modifications have been designed. These novel drugs are, however, mostly preclinical, and many problems continue to be unraveled. We have reviewed the current status of all TRAIL-based monotherapies and combination therapies that have reached phase II and phase III clinical trials in humans. We have also aimed to introduce all novel approaches of TRAIL utilization in cancer treatment and discussed the most promising drugs which are likely to enter clinical trials in humans. To date, different strategies were introduced in order to activate anti-tumor immune responses with the aim of achieving the highest efficacy and minimal toxicity.In this review, we discuss the most promising TRAIL-based clinical trials and their therapeutic strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018185
003      
CZ-PrNML
005      
20240216090830.0
007      
ta
008      
210726e20210310sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmolb.2021.628332 $2 doi
035    __
$a (PubMed)33791337
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Snajdauf, Martin $u Third Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
245    14
$a The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials / $c M. Snajdauf, K. Havlova, J. Vachtenheim, A. Ozaniak, R. Lischke, J. Bartunkova, D. Smrz, Z. Strizova
520    9_
$a TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) and its death receptors TRAIL-R1 and TRAIL-R2 selectively trigger the apoptotic cell death in tumor cells. For that reason, TRAIL has been extensively studied as a target of cancer therapy. In spite of the promising preclinical observations, the TRAIL-based therapies in humans have certain limitations. The two main therapeutic approaches are based on either an administration of TRAIL-receptor (TRAIL-R) agonists or a recombinant TRAIL. These approaches, however, seem to elicit a limited therapeutic efficacy, and only a few drugs have entered the phase II clinical trials. To deliver TRAIL-based therapies with higher anti-tumor potential several novel TRAIL-derivates and modifications have been designed. These novel drugs are, however, mostly preclinical, and many problems continue to be unraveled. We have reviewed the current status of all TRAIL-based monotherapies and combination therapies that have reached phase II and phase III clinical trials in humans. We have also aimed to introduce all novel approaches of TRAIL utilization in cancer treatment and discussed the most promising drugs which are likely to enter clinical trials in humans. To date, different strategies were introduced in order to activate anti-tumor immune responses with the aim of achieving the highest efficacy and minimal toxicity.In this review, we discuss the most promising TRAIL-based clinical trials and their therapeutic strategies.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Havlova, Klara $u Department of Urology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Vachtenheim, Jiri $u Third Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Ozaniak, Andrej $u Third Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia $7 xx0251893
700    1_
$a Lischke, Robert $u Third Department of Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Bartunkova, Jirina $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Smrz, Daniel $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Strizova, Zuzana $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
773    0_
$w MED00188065 $t Frontiers in molecular biosciences $x 2296-889X $g Roč. 8 (20210310), s. 628332
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33791337 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20240216090824 $b ABA008
999    __
$a ind $b bmc $g 1676569 $s 1138629
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 8 $c - $d 628332 $e 20210310 $i 2296-889X $m Frontiers in molecular biosciences $n Front Mol Biosci $x MED00188065
LZP    __
$a Pubmed-20210726

Find record

Citation metrics

Archiving options